title: Intracoronary injection of CD34-cells in chronic ischemic heart failure: 7 years follow-up of the DanCell study.
abstract: OBJECTIVE
  Seven years ago, the DanCell study was carried out to test the hypothesis of improvement in left ventricular ejection fraction (LVEF) following repeated intracoronary injections of autologous bone marrow-derived stem cells (BMSCs) in patients suffering from chronic ischemic heart failure. In this post hoc analysis, the long-term effect of therapy is assessed.
  
  
  METHODS
  32 patients [mean age 61 (SD ± 9), 81% males] with systolic dysfunction (LVEF 33 ± 9%) received two repeated intracoronary infusions (4 months apart) of autologous BMSCs (1,533 ± 765 × 10(6) BMSCs including 23 ± 11 × 10(6) CD34(+) cells and 14 ± 7 × 10(6) CD133(+) cells). Patients were followed for 7 years and deaths were recorded.
  
  
  RESULTS
  During follow-up, 10 patients died (31%). In univariate regression analysis, the total number of BMSCs, CD34(+) cell count and CD133(+) cell count did not significantly correlate with survival (hazard ratio: 0.999, 95% CI: 0.998-1.000, p = 0.24; hazard ratio: 0.94, 95% CI: 0.88-1.01, p = 0.10, and hazard ratio: 0.96, 95% CI: 0.87-1.07, p = 0.47, respectively). After adjustment for baseline variables in multivariate regression analysis, the CD34(+) cell count was significantly associated with survival (hazard ratio: 0.90, 95% CI: 0.82-1.00, p = 0.04).
  
  
  CONCLUSIONS
  Intracoronary injections of a high number of CD34(+) cells may have a beneficial effect on chronic ischemic heart failure in terms of long-term survival.
authors.affiliation: Department of Cardiology, Odense University Hospital, Odense, Denmark.
authors.forename: Morten
authors.initials: M
authors.lastname: Hansen
authors.forename: Sebastian
authors.initials: S
authors.lastname: Nyby
authors.forename: Jacob
authors.initials: J
authors.lastname: Eifer Møller
authors.forename: Lars
authors.initials: L
authors.lastname: Videbæk
authors.forename: Moustapha
authors.initials: M
authors.lastname: Kassem
authors.forename: Torben
authors.initials: T
authors.lastname: Barington
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.forename: Axel Cosmus Pyndt
authors.initials: AC
authors.lastname: Diederichsen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018952:Antigens, CD34; D016026:Bone Marrow Transplantation / Q000379:methods; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D036502:Infusions, Intralesional; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000628:therapy; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous / Q000379:methods; D016896:Treatment Outcome; D018487:Ventricular Dysfunction, Left / Q000628:therapy; D055815:Young Adult
chemical_list: D018952:Antigens, CD34